Phosplatin Therapeutics Doses First Patient in Phase 2 Study of PT-112 in Metastatic Castration Resistant Prostate Cancer Patients

USA - English

• USA - Français
• USA - Deutsch
• USA - English

NEW YORK, Oct. 22, 2020 /PRNewswire/ -- Phosplatin Therapeutics, a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that the first patient has been dosed in the Phase 2 study of PT-112 in patients with metastatic castration-resistant prostate cancer (mCRPC). The Phase II study builds upon encouraging signals of drug activity observed in Phase 1 studies previously reported, and will enroll up to 60 patients. PT-112 is a small-molecule immunogenic cell death inducer that is the first pyrophosphate conjugate under active development within anti-cancer therapy. The pyrophosphate component of PT-112 engenders osteotropism that is advantageous in dealing with mCRPC that metastasizes to the bone.

"The initiation of this Phase 2 study represents a significant milestone for patients and our company, as we continue to assess PT-112 as a monotherapy in heavily pre-treated mCRPC patients, who currently have limited therapeutic options," said Joseph F. O'Donnell, MD, Interim Chief Medical Officer of Phosplatin. "Advanced metastatic prostate cancer is known to be immunologically 'cold' and to have an extremely high rate of bone metastatic disease. With PT-112's unique combination of immunogenic cell death induction and osteotropism, we hope to replicate positive results from our Phase 1 studies, including reduction in disease burden and pain."

The purpose of the Phase 2 multi-center, open-label study is to confirm the appropriate dose level and to evaluate preliminary evidence of efficacy of PT-112 in late-line mCRPC patients. Secondary objectives include a range of outcome measures that are derived from the Prostate Cancer Working Group 3 (PCWG3) criteria, along with exploratory endpoints and an array of correlative studies using patient samples.

Further information on this clinical trial (NCT 02266745) can be found at clinicaltrials.gov.

About PT-112

PT-112 is a novel small molecule conjugate of pyrophosphate that possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD) through the release of specific damage associated molecular patterns (DAMPs) that bind to dendritic cells and lead to downstream immune effector T-cell recruitment in the tumor microenvironment. PT-112 represents the best-in-class small molecule inducer of this immunological form of cancer cell death and is under Phase 2 development. The first in-human study of PT-112 demonstrated an attractive safety profile and evidence of long-lasting responses among heavily pre-treated patients and won "Best Poster" within the Developmental Therapeutics category at the ESMO 2018 Annual Congress. The novelty of PT-112's pyrophosphate moiety also results in osteotropism, or the propensity of the drug to reach the mineralized bone. This property is of interest in cancer types that originate in or metastasize to the bone. The first human clinical results in mCRPC were presented at the 2020 Genitourinary Cancers Symposium.

About Phosplatin Therapeutics

Phosplatin Therapeutics is a privately held, clinical stage pharmaceutical company that holds exclusive global license to phosphaplatins, a family of small molecules rationally designed to circumvent the mechanisms of drug resistance and toxicity commonly associated with cytotoxic regimens. The company's lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique combination of properties, including immunogenic cell death and osteotropism. Clinical data generated to date across three Phase 1 studies have demonstrated single agent anti-cancer activity and an attractive tolerability profile. The company's research and development work to date has spanned fifteen countries and been funded by private investors and family investment offices in the United States, Europe and Asia, along with a sub-license agreement for the development, commercialization and use of PT-112 in Greater China. The company also is sponsoring an ongoing clinical study of PT-112 in combination with the PD-L1 inhibitor avelumab under a collaboration agreement with Pfizer and Merck KGaA, Darmstadt, Germany (operating as EMD Serono in the US and Canada). Initial results of this study were recently reported in an oral presentation at the ESMO 2020 Virtual Congress.

CONTACTS:

Phosplatin Therapeutics
Taylor Young
Senior Director of Strategic Development
Tel:  +1 646 380 2441
Email: [email protected]

Westwicke, an ICR Company
Investors:
Stephanie Carrington
Tel: +1 646 277 1282 
Email: [email protected] 

Media: 
Mark Corbae
Tel: +1 203 682 8288
Email: [email protected]

SOURCE Phosplatin Therapeutics

Related Links

http://phosplatin.com